Inventor
LUTTERBÜSE Ralf
DE20 patents
⚠️ This page may combine multiple inventors who share the name “LUTTERBÜSE Ralf”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN RES MUNICH GMBH
16 patentsUS10294300B2May 21, 2019
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH37 citations97
US9982063B2May 29, 2018
Pharmaceutical compositions with resistance to soluble CEA
AMGEN RES MUNICH GMBH14 citations90
US11591396B2Feb 28, 2023
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH5 citations85
US10683351B2Jun 16, 2020
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH4 citations83
US10059766B2Aug 28, 2018
Antibody constructs for CDH19 and CD3
AMGEN RES MUNICH GMBH9 citations82
US11661462B2May 30, 2023
Optimized cross-species specific bispecific single chain antibody contructs
AMGEN RES MUNICH GMBH4 citations73
US11472886B2Oct 18, 2022
Cross-species-specific PSMAxCD3 bispecific single chain antibody
AMGEN RES MUNICH GMBH3 citations71
US9695250B2Jul 4, 2017
Pharmaceutical compositions with resistance to soluble CEA
AMGEN RES MUNICH GMBH4 citations71
US10851170B2Dec 1, 2020
Antibody constructs for CD70 and CD3
AMGEN RES MUNICH GMBH3 citations67
US12435139B2Oct 7, 2025
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH0 citations62
US12304952B2May 20, 2025
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH0 citations62
US11987633B2May 21, 2024
Cross-species-specific single domain bispecific single chain antibody
AMGEN RES MUNICH GMBH1 citations62
US11498964B2Nov 15, 2022
Antibody constructs for CDH19 and CD3
AMGEN RES MUNICH GMBH1 citations61
US12281172B2Apr 22, 2025
Cross-species-specific PSMAxCD3 bispecific single chain antibody
AMGEN RES MUNICH GMBH0 citations60
US11926666B2Mar 12, 2024
Bispecific antibody constructs for CDH3 and CD3
AMGEN RES MUNICH GMBH0 citations57
US11028171B2Jun 8, 2021
Bispecific antibody constructs for CDH3 and CD3
AMGEN RES MUNICH GMBH1 citations57